ANGO AngioDynamics, Inc. - Fundamental Analysis
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Valuation metrics are distorted by sustained losses; no reliable P/E or PEG for assessment.
- Price/Book of 2.50 is moderate relative to peers
- Gross margin of 54.58% suggests operational efficiency
- No Graham Number or intrinsic value formula available
- Forward P/E of -96.36 invalidates traditional valuation
- Price/Sales of 1.42 is elevated for a loss-making firm
Growth is present but not translating into earnings; future profitability remains highly uncertain.
- 9% YoY revenue growth indicates top-line momentum
- Historical earnings surprises average +56.53%, suggesting potential for beat-and-raise scenarios
- Negative year-over-year EPS growth (-136.4%) and Q/Q EPS decline (-766.7%) signal deteriorating profitability
- Forward P/E of -96.36 implies continued losses
Past performance shows strong earnings execution but remains inconsistent and unprofitable.
- Consistent earnings beat rate of 2/4 in the last 4 quarters
- High average earnings surprise (+56.53%) over 25 quarters
- Frequent negative earnings surprises (e.g., -300%, -166.7%) indicate volatility
- Long history of losses, including multiple quarters with negative EPS
Balance sheet is strong, but operational health is critically weak; Piotroski score confirms distress.
- Debt/Equity of 0.07 is exceptionally low
- Current ratio of 2.24 and quick ratio of 1.20 indicate strong liquidity
- Piotroski F-Score of 1/9 is among the weakest possible
- No Altman Z-Score available, but negative ROE and ROA suggest distress risk
- Negative ROIC and lack of free cash flow data raise capital efficiency concerns
No dividend policy in place; not applicable for income investors.
- No dividend yield or payout ratio
- Dividend strength score of 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ANGO and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ANGO
AngioDynamics, Inc.
Primary
|
-53.3% | -14.0% | +16.2% | -0.5% | -6.8% | -2.1% |
|
ALT
Altimmune, Inc.
Peer
|
-80.3% | -68.4% | -32.7% | -3.9% | -24.4% | -1.1% |
|
ACRS
Aclaris Therapeutics, Inc.
Peer
|
-85.2% | -56.5% | +126.9% | +81.5% | +4.4% | +15.7% |
|
ADCT
ADC Therapeutics SA
Peer
|
-89.4% | -22.9% | +105.1% | +10.1% | +2.3% | -0.3% |
|
AUNA
Auna SA
Peer
|
-41.0% | -41.0% | -30.8% | -9.7% | +21.7% | +22.2% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ANGO
AngioDynamics, Inc.
|
BEARISH | $436.9M | - | -15.3% | -9.0% | $10.6 | |
|
ALT
Altimmune, Inc.
|
BEARISH | $438.31M | - | -50.6% | -% | $3.5 | |
|
ACRS
Aclaris Therapeutics, Inc.
|
BEARISH | $428.65M | - | -50.2% | -% | $3.54 | |
|
ADCT
ADC Therapeutics SA
|
NEUTRAL | $447.2M | - | -% | -222.0% | $3.61 | |
|
AUNA
Auna SA
|
NEUTRAL | $418.91M | 5.78 | 11.4% | 4.3% | $5.66 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-10-21 | LAWRENCE WEISS T | Officer | Purchase | 10,000 | $118,100 |
| 2025-10-13 | TROWBRIDGE STEPHEN A | Chief Financial Officer | Purchase | 890 | $9,932 |
| 2025-10-09 | CLEMMER JAMES C | Chief Executive Officer | Purchase | 10,000 | $111,500 |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning ANGO from our newsroom.